Segantii Capital Management’s Lipocine LPCN Stock Holding History

Segantii Capital Management’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,235	Closed	-$219K	–	78
2016 Q1	$219K	Buy	+1,235	New	+$211K	0.09%	71

Other funds holding LPCN

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Segantii Capital Management's LPCN Position: Q2 2016 in Review

Segantii Capital Management sold out of Lipocine (LPCN) in Q2 2016, closing a stake of 1,235 shares — an estimated $219K sold.

Segantii Capital Management first reported a position in LPCN in Q1 2016 and held it in 1 quarter. The position peaked at $219K in Q1 2016. 54 funds tracked by Wall St. Rank hold LPCN as of Q2 2016.

Segantii Capital Management reported no remaining Lipocine position as of Q2 2016 after selling out during the quarter.
Segantii Capital Management sold 1,235 Lipocine shares in Q2 2016, an estimated $219K.
Segantii Capital Management first reported a position in Lipocine in Q1 2016 and held it in 1 quarter.
Segantii Capital Management's Lipocine position peaked at $219K in Q1 2016.
54 funds tracked by Wall St. Rank held Lipocine as of Q2 2016.

Based on Segantii Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.